WHAT DOES ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) MEAN?

In Segment A, participants will get diverse doses and schedules of oral ABBV-744 tablet to discover Risk-free dosing program. More individuals will likely be enrolled in the determined monotherapy dosign regimen. In Phase B, individuals will acquire oral ruxolitinib and ABBV-744 will be specified as "incorporate-on" therapy. In Segment C, members w